Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
05 mars 2024 16h05 HE
|
Gritstone bio
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC)...
Gritstone bio Announces Workforce Reduction
29 févr. 2024 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
21 févr. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
12 févr. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 févr. 2024 16h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor Conference
17 janv. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 janv. 2024 16h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 déc. 2023 16h30 HE
|
Gritstone bio
EMERYVILLE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone bio to Participate in Upcoming Investor Conferences
20 nov. 2023 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
08 nov. 2023 16h05 HE
|
Gritstone bio
-- BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b...